Datroway is approved by FDA for metastatic HR-positive, HER2-negative breast cancer after prior endocrine and chemotherapy based on TROPION-Breast01 Phase 3 results 

AstraZeneca highlights Datroway’s approval as the 8th of 20 new medicines planned by 2030 

TROPION-Breast01 results shows Datroway reduced the risk of disease progression or death by 37% compared to chemotherapy (HR 0.63, p<0.0001) 

mPFS was 6.9 months with vs. 4.9 months with chemotherapy 

It showed no new safety concerns, with an interstitial lung disease rate of 4.2%, mostly low-grade events 

Datroway is discovered by Daiichi Sankyo and jointly developed and commercialized by AstraZeneca and Daiichi Sankyo 

Additional submissions for breast cancer under review in the EU, China, and other regions